Lilly buys AtaiBeckley·$3.8bn Otsuka buys Transcend·$1.2bn AbbVie buys Gilgamesh·$1.2bn atai buys Beckley Psytech·terms undisclosed AbbVie takes an option on Gilgamesh·$2bn Lilly buys AtaiBeckley·$3.8bn Otsuka buys Transcend·$1.2bn AbbVie buys Gilgamesh·$1.2bn atai buys Beckley Psytech·terms undisclosed AbbVie takes an option on Gilgamesh·$2bn Lilly buys AtaiBeckley·$3.8bn Otsuka buys Transcend·$1.2bn AbbVie buys Gilgamesh·$1.2bn atai buys Beckley Psytech·terms undisclosed AbbVie takes an option on Gilgamesh·$2bn

Next issueIssue 16 · Tue 29 Sep

Assets

The molecules this publication tracks, each with its owner, its phase and every registry record that names it. Generated from data/assets.csv.

BPL-003Beckley Psytech / AtaiBeckley5 trialsPhase 2b complete
brenipatide (LY3537031)Lilly9 trialsPhase 3 in MDD (two pivotals) and alcohol use disorder (two pivotals)
COMP360Compass Pathways3 trialsPhase 3 complete (COMP005, COMP006)
CYB003Cybin3 trialsPhase 3 recruiting
DT120 (registry title MM120)Definium Therapeutics5 trialsPhase 3 across four trials
GH001GH Research4 trialsPhase 2b complete
MDMA hydrochloride (investigator-led)Amsterdam UMC1 trialPhase 2 authorised
psilocybin (investigator-led; PEX010 capsules, 25 mg and 5 mg)ARQ Centrum'452 trialsPhase 2 not yet recruiting
psilocybin (investigator-led; PEX010)Slagelse Hospital1 trialPhase 2 authorised
psilocybin (investigator-led)Region Skane2 trialsPhase 2 recruiting
psilocybin with trazodone (investigator-led; PEX010 25 mg and Trittico)University of Chieti-Pescara1 trialPhase 2a authorised
VLS-01atai Therapeutics1 trialPhase 2b